Antelope Dx, a Ghent-based company developing a palm-sized diagnostic device for home testing, has received €9 million in Series B funding to start clinical stages of a test for certain sexually-transmitted diseases. The round’s investments were split down the middle between Whitefund and existing investors that participated in a €5.1 million Series A one year ago.

Specifically, the device is a urine-based test for Chlamydia trachomatis and Neisseria gonorrhea. The team is also developing tests for respiratory Influenza A/B and Sars-CoV-2, which people can do at home using a single swab sample.

Antelope says its technology is unique because it hits three goals that one rarely finds in a single diagnostic device: “clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag.” The platform is based on lab-on-chip technology that can perform tests on any bodily fluid — urine, blood, mucus, etc. — without any complex demands on the user.

The startup, which is built on ten years of research at the Photonics Research Group of Ghent University and spun out from Belgian biotech company MyCartis last summer, has also raised several million in grants from the Flanders Agency for Innovation and Entrepreneurship (VLAIO).

Comments are closed.